PhoenixBio Co., Ltd.

Tokyo Stock Exchange 6190.T

PhoenixBio Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2024: USD 9.15 M

PhoenixBio Co., Ltd. Cash and Short-Term Investments is USD 9.15 M for the year ending March 31, 2024, a -21.83% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • PhoenixBio Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2023 was USD 11.71 M, a 7.51% change year over year.
  • PhoenixBio Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2022 was USD 10.89 M, a -9.18% change year over year.
  • PhoenixBio Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2021 was USD 11.99 M, a -27.38% change year over year.
  • PhoenixBio Co., Ltd. Cash and Short-Term Investments for the year ending March 31, 2020 was USD 16.51 M.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
SV Wall Street
Tokyo Stock Exchange: 6190.T

PhoenixBio Co., Ltd.

CEO Takashi Shimada
IPO Date March 18, 2016
Location Japan
Headquarters 3-4-1 Kagamiyama
Employees 70
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.

StockViz Staff

January 31, 2025

Any question? Send us an email